Mereo BioPharma Group

NAQ:MREO · US5894921072

BiotechnologyX-Small

360

Medium confidence — indicative

Value—

Profit price—

Cash yield1

Sales & asset price48

Price/Sales50

EV / Gross Profit39

Price/Book56

Quality46

Returns on capital35

Return on Capital32

Return on Equity37

Profit margins39

Cash truth not applicable for financial companies.

Growth56

Sales growth100

Profit growth50

Reinvestment6

Price momentum1

Safety49

Debt load93

Debt serviceability16

Liquidity12

Sentiment50

Analyst ratings19

Expectations trend50

Market mood29

Value Creation7/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Mereo BioPharma Group clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUK

IndustryBiotechnology

SizeX-Small

TypePublic Company

ExchangeNASDAQCM

Founded2015

Employees41

Websitemereobiopharma.com

ISINUS5894921072

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Stem Cell TherapyChronic DiseasesPulmonologyRespiratoryImmunologyOsteoporosisOncologyGeneticsBiotechnologyHealth CareProfessional ServicesScience and Engineering

Description

Mereo BioPharma Group plc (Mereo) is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. Mereo has developed a portfolio of late-stage clinical product candidates. The company’s two rare disease produ…

Analysis

Middle-of-the-road

Mereo BioPharma Group plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 7/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Mereo BioPharma Group with its peers

Kuros Biosciences

SWX:KURN

CountrySwitzerland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Immunocore

NSQ:IMCR

CountryUK

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zealand Pharma

CPH:ZEAL

CountryDenmark

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Prothena Corporation

NSQ:PRTA

CountryIreland

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tiziana Life Sciences

NAQ:TLSA

CountryUK

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

argenx

BRU:ARGX

CountryNetherlands

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →